ArticleThe Journal of rheumatology2020
Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence.
Article in The Journal of rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Efficacy and safety of 10 mg versus 30 mg of oral prednisolone for acute CPP crystal arthritis: findings of a randomized controlled trial.Clinical rheumatology · 2024Trial
- Expert Perspective: Treatment of Patients With Calcium Pyrophosphate Deposition Disease: Where Do We Begin and Where Are We Going?Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Development and internal-external cross-validation of a patient-reported definition for acute calcium pyrophosphate crystal arthritis.Rheumatology (Oxford, England) · 2025Article
- Features Associated With Different Inflammatory Phenotypes of Calcium Pyrophosphate Deposition Disease: A Study Using Data From the International American College of Rheumatology/EULAR Calcium Pyrophosphate Deposition Classification Criteria Cohort.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned?Rheumatology (Oxford, England) · 2024Article
- An Update on the Diagnosis and Management of Calcium Crystal Disease.Current rheumatology reports · 2023Review
- Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis.Annals of the rheumatic diseases · 2022Article
- Review: Outcome measures in calcium pyrophosphate deposition.Best practice & research. Clinical rheumatology · 2021Review
- Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.Seminars in arthritis and rheumatism · 2021Review
- A critical review of the available evidence on the diagnosis and clinical features of CPPD: do we really need imaging?Clinical rheumatology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveLittle is known about acute calcium pyrophosphate (CPP) crystal arthritis flare rates and risk factors for recurrence. We characterized flares and determined the rate and predictors of acute CPP crystal arthritis flares in an academic medical center cohort.
methodsWe performed a retrospective cohort study among a random sample of patients with acute CPP crystal arthritis identified in the Partners HealthCare electronic medical record, 1991-2017. Flare was defined as self-limited, acute-onset synovitis with synovial fluid CPP crystals and/or chondrocalcinosis, not better explained by another cause. We calculated incidence rates (IR) for acute CPP crystal arthritis flare among all subjects and by sex. We estimated HR for recurrent flare using univariate Cox models that accounted for within-person correlated data.
resultsWe identified 70 patients with acute CPP crystal arthritis with a total of 111 flares. Recurrent flares occurred in 24% of patients; half of flares occurred in a previously unaffected joint. The acute CPP crystal arthritis flare rate was 11.4 per 100 person-years overall (95% CI 8.2-15.4), 14.2 in women (95% CI 9.6-0.1), and 7.1 in men (95% CI 3.4-13.0). Cancer (HR 2.98, 95% CI 1.33-6.68) and chronic kidney disease (HR 2.92, 95% CI 1.10-7.76) were associated with a higher rate for recurrent flare.
conclusionRecurrent flares occurred in about one-fourth of patients with acute CPP crystal arthritis and often occurred in previously unaffected joints. The acute CPP crystal arthritis flare rate was twice as high in women as in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.